Atrium Therapeutics RNA 深 沪
等待开盘 07-01 09:30:00 美东时间
13.45
-0.200
-1.47%
华盛通- 最 高13.80
- 今 开13.67
- 成交量 31.61万股
- 最 低 13.22
- 昨 收 13.65
- 总市值 2.30亿
- 52周最高 73.06
- 市盈率 静 --
- 换手率 1.85%
- 52周最低 11.4031
- 委 比 -89.22%
- 总股本 1710.56万
- 历史最高 73.06
- 量 比 0.89
- 振 幅 4.25%
- 历史最低 4.825
- 每 手 1
- 风险率 24.16%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Cantor Fitzgerald Initiates Coverage On Atrium Therapeutics with Overweight Rating, Announces Price Target of $25
Cantor Fitzgerald analyst Kristen Kluska initiates coverage on Atrium Therapeutics (NASDAQ:RNA) with a Overweight rating and announces Price Target of $25.
06-18 20:50
美股大行评级 | 应用材料获17家大行集体上调目标价；Bitdeer 、Forgent 、嘉信理财、Viking等获多家大行上调目标价
今日重点评级关注：Chardan Capital：维持Senti Biosciences"买入"评级，目标价从11美元升至12美元；Ladenburg Thalmann：维持Usio"买入"评级，目标价从5.75美元升至6.25美元
05-18 11:48
Leerink Partners Initiates Coverage On Atrium Therapeutics with Outperform Rating, Announces Price Target of $25
Leerink Partners analyst Joseph Schwartz initiates coverage on Atrium Therapeutics (NASDAQ:RNA) with a Outperform rating and announces Price Target of $25.
05-16 01:34
Atrium Therapeutics Q1净亏损1660万美元，BMS里程碑付款支撑收入
核心财务数据 Atrium Therapeutics公布2026年第一季度财报。公司报告期内净亏损为1663万美元，合每股亏损0.97美元。作为对比，公...
05-15 23:41
财报速睇 | Atrium Therapeutics 2026财年Q1营收0.20亿美元，同比增长900.0%；归母净利润亏损0.17亿美元，同比亏损扩大142.9%
华盛资讯5月15日讯，Atrium Therapeutics公布2026财年Q1业绩，公司Q1营收0.20亿美元，同比增长900.0%，归母净利润亏损0.17亿美元，同比亏损扩大142.9%。
05-15 07:32
Atrium Therapeutics Q1 EPS $(0.97) Beats $(1.10) Estimate, Sales $19.635M Beat $2.000M Estimate
Atrium Therapeutics (NASDAQ:RNA) reported quarterly losses of $(0.97) per share which beat the analyst consensus estimate of $(1.10) by 11.82 percent. This is a 7.78 percent decrease over losses of $(0.90) per share from
05-15 04:47
HC Wainwright & Co. Suspends Neutral Rating on Atrium Therapeutics
HC Wainwright & Co. suspends Neutral rating on Atrium Therapeutics (NASDAQ:RNA).
05-01 19:11
Top 3 Health Care Stocks That Could Lead To Your Biggest Gains This Month
Oversold stocks in health care sector present buying opportunity. RSI compares stock's strength on up/down days & predicts short-term performance. Top oversold stocks: KNSA (28) NNOX (28.2) RNA (28.4).
04-21 18:26
Atrium Therapeutics grants inducement equity awards to seven new hires under Nasdaq rule
Atrium Therapeutics grants inducement equity awards to seven new hires under Nasdaq rule Atrium Therapeutics granted inducement equity awards to seven newly hired non-executive employees under its 2026 Employment Inducement Incentive Award Plan. Grants total 101,250 non-qualified stock options with
04-21 11:05
